Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: A multiple-treatments meta-analysis

BMJ Open

Volumn 7, Issue 8, 2017, Pages

  Sun, Yefei ^a   Liang, Yifan ^a   Jiao, Yang ^a   Lin, Jueying ^b   Qu, Huiling ^c   Xu, Junjie ^a   Zhao, Chuansheng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^c People's Hospital of Liaoning Province   (China)

Author keywords

antidepressant treatment; multiple treatments meta analysis; post stroke depression

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DOXEPIN; DULOXETINE; FLUOXETINE; NEFIRACETAM; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; TRAZODONE; MORPHOLINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; POST-STROKE DEPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT DURATION; AGED; COMPARATIVE STUDY; DEPRESSION; FEMALE; MALE; PATIENT ATTITUDE; PSYCHOLOGY; TREATMENT OUTCOME;

AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSION; DEPRESSIVE DISORDER; DOXEPIN; DULOXETINE HYDROCHLORIDE; FEMALE; FLUOXETINE; HUMANS; MALE; MORPHOLINES; PAROXETINE; PATIENT ACCEPTANCE OF HEALTH CARE; SEROTONIN UPTAKE INHIBITORS; STROKE; TREATMENT OUTCOME;

EID: 85027003527     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-016499     Document Type: Article

References (52)

1. Towfghi A, Ovbiagele B, El Husseini N, et al. Poststroke Depression: A Scientifc Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2017;48.
2. Wulsin L, Alwell K, Moomaw CJ, et al. Comparison of two depression measures for predicting stroke outcomes. J Psychosom Res 2012;72:175-9.
3. Willey JZ, Disla N, Moon Y P, et al. Early depressed mood after stroke predicts long-term disability: the Northern Manhattan Stroke Study (NOMASS). Stroke 2010;41:1896-900.
4. Kim JH, Park EY. The factor structure of the center for epidemiologic studies depression scale in stroke patients. Top Stroke Rehabil 2012;19:54-62.
5. Jørgensen TS, Wium-Andersen IK, Wium-Andersen MK, et al. Incidence of Depression After Stroke, and Associated Risk Factors and Mortality Outcomes, in a Large Cohort of Danish Patients. JAMA Psychiatry 2016;73:1032-40.
6. Meader N, Moe-Byrne T, Llewellyn A, et al. Screening for poststroke major depression: a meta-analysis of diagnostic validity studies. J Neurol Neurosurg Psychiatry 2014;85:198-206.
7. Xu XM, Zou DZ, Shen LY, et al. Effcacy and feasibility of antidepressant treatment in patients with post-stroke depression. Medicine 2016;95:e5349.
8. Hackett ML, Anderson CS, House A, et al. Interventions for preventing depression after stroke. Cochrane Database Syst Rev 2008:CD003689.
9. Holloway RG, Arnold RM, Creutzfeldt CJ, et al. Palliative and end-of-life care in stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:1887-916.
10. Hackett ML, Yapa C, Parag V, et al. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005;36:1330-40.
11. Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke 2014;9:1017-25.
12. Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2008:CD003437.
13. Winstein CJ, Stein J, Arena R, et al. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2016;47:e98-e169.
14. Salanti G, Higgins J P, Ades AE, et al. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
15. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:1-19.
16. Eskes GA, Lanctôt KL, Herrmann N, et al. Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue Following Stroke practice guidelines, update 2015. Int J Stroke 2015;10:1130-40.
17. Intercollegiate Stroke Working Party. National clinical guideline for stroke. 4th edition: Royal College of Physicians, 2012.
18. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: The Cochrane Collaborationk, 2011. www.cochrane-handbook.org
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
20. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0, 2011. http://www. cochrane-handbook. org (accessed 9 Apr 2015).
21. White IR. Multivariate random-effects meta-regression: updates to mvmeta. The STATA Journal 2011;11:255-70.
22. White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 2012;3:111-25.
23. Chaimani A, Higgins J P, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8:e76654.
24. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefts, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3:80-97.
25. Veroniki AA, Vasiliadis HS, Higgins J P, et al. Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013;42:332-45.
26. Salanti G, Marinho V, Higgins J P, et al. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol 2009;62:857-64.
27. Robinson RG, Morris PL, Fedoroff J P, et al. Depression and cerebrovascular disease. J Clin Psychiatry 1990;51:26-33.
28. Parikh RM, Robinson RG, Lipsey JR, et al. The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol 1990;47:785-9.
29. Morris PL, Robinson RG, Andrzejewski P, et al. Association of depression with 10-year poststroke mortality. Am J Psychiatry 1993;150:124-9.
30. Angeleri F, Angeleri VA, Foschi N, et al. The infuence of depression, social activity, and family stress on functional outcome after stroke. Stroke 1993;24:1478-83.
31. Andersen G, Vestergaard K, Lauritzen L, et al. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099-104.
32. Chen W, Wang G-F, Chen X-H, et al. Effects of paroxetine on function recovery in patients with poststroke depression. Chinese J Clin Rehabil 2002;6:2014-5.
33. Fruehwald S, Gatterbauer E, Rehak P, et al. Early fuoxetine treatment of post-stroke depression-a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003;250:347-51.
34. Karaiskos D, Tzavellas E, Spengos K, et al. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. J Neuropsychiatry Clin Neurosci 2012;24:349-53.
35. Kimura M, Robinson RG, Kosier JT, et al. Treatment of cognitive impairment after poststroke depression: a double-blind treatment trial. Stroke 2000;31:1482-6.
36. Lipsey JR, Robinson RG, Pearlson GD, et al. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1984;1:297-300.
37. Murray V, von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 2005;66:708-16.
38. Raffaele R, Rampello L, Vecchio I, et al. Trazodone therapy of the post-stroke depression. Arch Gerontol Geriatr 1996;22(Suppl 1):217-20.
39. Rampello L, Alvano A, Chiechio S, et al. An evaluation of effcacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study. Arch Gerontol Geriatr 2005;40:275-85.
40. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fuoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000;157:351-9.
41. Robinson RG, Jorge RE, Clarence-Smith K, et al. Double-blind randomized treatment of poststroke depression using nefracetam. J Neuropsychiatry Clin Neurosci 2008;20:178-84.
42. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31:1829-32.
43. Robinson RG, Jorge RE. Post-Stroke Depression: a Review. Am J Psychiatry 2016;173:221-31.
44. Rampello L, Nicoletti G, Raffaele R, et al. Comparative effects of amitriptyline and amineptine in patients affected by anxious depression. Neuropsychobiology 1995;31:130-4.
45. Rampello L, Nicoletti G, Raffaele R, et al. Dopaminergic hypothesis for retarded depression: a symptom profle for predicting therapeutical responses. Acta Psychiatr Scand 1991;84:552-4.
46. Alajbegovic A, Djelilovic-Vranic J, Nakicevic A, et al. Post stroke depression. Med Arch 2014;68:47-50.
47. Wei N, Yong W, Li X, et al. Post-stroke depression and lesion location: a systematic review. J Neurol 2015;262:81-90.
48. Tan S, Huang X, Ding L, et al. Effcacy and safety of citalopram in treating post-stroke depression: a meta-analysis. Eur Neurol 2015;74:188-201.
49. Bhogal SK, Teasell R, Foley N, et al. Heterocyclics and selective serotonin reuptake inhibitors in the treatment and prevention of poststroke depression. J Am Geriatr Soc 2005;53:1051-7.
50. Hackett ML, Anderson CS, House AO, et al. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 2005;36:1092-7.
51. Chen Y, Guo JJ. Meta-analysis of antidepressant treatment for patients with poststroke depression. Stroke 2006;37:1365-6.
52. Chen Y, Guo JJ, Zhan S, et al. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother 2006;40:2115-22.